CN102920788A - Preparation method of non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis for treating gastric ulcer - Google Patents
Preparation method of non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis for treating gastric ulcer Download PDFInfo
- Publication number
- CN102920788A CN102920788A CN2012104647581A CN201210464758A CN102920788A CN 102920788 A CN102920788 A CN 102920788A CN 2012104647581 A CN2012104647581 A CN 2012104647581A CN 201210464758 A CN201210464758 A CN 201210464758A CN 102920788 A CN102920788 A CN 102920788A
- Authority
- CN
- China
- Prior art keywords
- alkaloid
- fructus toosendan
- rhizoma corydalis
- preparation
- gastric ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A preparation method of non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis for treating a gastric ulcer relates to a preparation method of the non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis. The preparation method solves the problems that the existing Western medicines for treating the gastric ulcer have side effects, and the traditional Chinese medicine fructus toosendan powder is inconvenient to take and is large in dose. The method is as follows: firstly, mixing the fructus toosendan and the rhizoma corydalis for water extraction; secondly, performing alcohol extraction on concentrated solution to obtain a neutral ion exchange liquid containing the non-alkaloid components; thirdly, condensing the neutral ion exchange liquid containing the non-alkaloid components to obtain a non-alkaloid paste, and drying to obtain the non-alkaloid powder; and fourthly, preparing the non-alkaloid powder, the starch and the purified water into pills, and namely the preparation of the non-alkaloid pills. The medicine provided by the invention is more stable in components, lower in cost, more convenient in use and better in efficacy. The effect of the non-alkaloid pills on treatment of the gastric ulcer is equivalent to the typical Western medicine omeprazole for treating the gastric ulcer, but the side effect is eliminated; and compared with the fructus toosendan powder, the non-alkaloid pills are more convenient to take and less in dose.
Description
Technical field
The present invention relates to the preparation method of the non-alkaloid ball of Fructus Toosendan and Rhizoma Corydalis extraction.
Background technology
Gastric ulcer is commonly encountered diseases and frequently-occurring disease clinically, and be the disease that heals than refractory clinically always, have the sickness rate height, the relapse rate after the alleviation is high characteristics also, have a strong impact on Quality of Life, bringing heavy economy and psychological burden for society and family.Modern medicine is in its Therapeutic Method, and operation has certain traumatic, be difficult for being accepted by the patient, and the treatment of Western medicine often gastric acid inhibitory secretion, kill the temporary remission method such as helicobacter pylori, and certain side effect is arranged.Motherland's medical science is classified it as " stomachache " category, and according to the principle of determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, clinical efficacy is reliable aspect treatment, and wherein Sichuan Chinaberry Powder is the recipe of all pain cards for the treatment of trusted subordinate's gastral cavilty, and curative effect is better, and uses safety.Sichuan Chinaberry Powder is comprised of Fructus Toosendan (having another name called Fructus Toosendan), Rhizoma Corydalis two flavors; But its effective substance that plays a role is still not clear, and relevant experimentation is very few, lacks systematicness, and needs of patients is lower with the rear clothes of wine accent, takes trouble, and consumption is large, brings inconvenience to the patient.
Summary of the invention
The present invention seeks to has side effect for the Western medicine that solves existing treatment gastric ulcer, and the Chinese medicine Sichuan Chinaberry Powder exists again takes inconvenience and the large problem of consumption, and is provided for treating the preparation method of Fructus Toosendan and the non-alkaloid ball that Rhizoma Corydalis extracts of gastric ulcer.
Being used for the treatment of the Fructus Toosendan of gastric ulcer and the preparation method of the non-alkaloid ball that Rhizoma Corydalis extracts carries out as follows:
One, the Rhizoma Corydalis of 1.25～3.75Kg and the Fructus Toosendan of 2.5Kg are mixed, then add the distilled water account for 8 times of Rhizoma Corydalis and Fructus Toosendan gross masses and decoct 2h, collect decoction liquor, add again the distilled water account for 6 times of Rhizoma Corydalis and Fructus Toosendan gross masses and decoct 2h, merge decoction liquor and also be concentrated into the concentrated solution that obtains 5000mL;
Two, adding mass concentration in the concentrated solution is that 95% ethanol to final concentration is 75%, filter after leaving standstill 24h, then steam the ethanol in the filtrate, add water to again 5000mL, adding concentrated hydrochloric acid hydrochloric acid final concentration to the solution is 5%, then crosses 731 type cation exchange resin columns, uses bismuth potassium iodide to detect at any time ion exchange liquid, collection contains the ion exchange liquid of non-alkaloid components, adds the NaOH adjust pH to neutral again in the ion exchange liquid that contains non-alkaloid components;
Three, the ion exchange liquid that contains non-alkaloid components of gained neutrality in the step 2 obtains the non-alkaloid cream that relative density is 1.15g/ml at 25～50 ℃ of lower concentrating under reduced pressure, and then drying makes the non-alkaloid powder under vacuum;
Four, get the non-alkaloid powder 100g that step 3 makes, then add the starch of 100g and the purified water of 50～100g and make pill, namely finish the preparation of the non-alkaloid ball that the Fructus Toosendan that is used for the treatment of gastric ulcer and Rhizoma Corydalis extract.
The present invention is used for the treatment of the preparation method of Fructus Toosendan and the non-alkaloid ball that Rhizoma Corydalis extracts of gastric ulcer, utilize traditional Chinese medical prescription to learn Compatibility Law, composition and special efficacy according to Rhizoma Corydalis and Fructus Toosendan, they are pressed the different proportion compatibility, and the non-alkaloid component of extracting wherein makes pill, is applied to treat gastric ulcer.
The present invention prepares the gained pill without adding chemical sweeting agent, shows that through animal acute toxicity experiment animal subject has no any toxic reaction, and nontoxic to organism, safety of medicine is reliable.Ingredient of the present invention is stable, and cost is lower, easy to use, and curative effect is better.From treatment rat model gastric ulcer effect, at ulcer index, serum il-8, TNF-α, NT, PAF, TXB
2With VEGF, cerebral tissue AchE, gastric tissue PGE
2And bFGF, VEGFmRNA and bFGFmRNA index of correlation data aspect, the pill that the present invention makes can promote the reparation that damages and the healing of ulcer effectively, has preferably effect to curing ulcer, the effect of its treatment ulcer can be suitable with treatment gastric ulcer typical case Western medicine omeprazole, but but eliminated side effect.And compare with Sichuan Chinaberry Powder, take more conveniently, consumption is little.
The specific embodiment
The specific embodiment one: present embodiment is used for the treatment of the Fructus Toosendan of gastric ulcer and the preparation method of the non-alkaloid ball that Rhizoma Corydalis extracts is carried out as follows:
One, the Rhizoma Corydalis of 1.25～3.75Kg and the Fructus Toosendan of 2.5Kg are mixed, then add the distilled water account for 8 times of Rhizoma Corydalis and Fructus Toosendan gross masses and decoct 2h, collect decoction liquor, add again the distilled water account for 6 times of Rhizoma Corydalis and Fructus Toosendan gross masses and decoct 2h, merge decoction liquor and also be concentrated into the concentrated solution that obtains 5000mL;
Two, adding mass concentration in the concentrated solution is that 95% ethanol to final concentration is 75%, filter after leaving standstill 24h, then steam the ethanol in the filtrate, add water to again 5000mL, adding concentrated hydrochloric acid hydrochloric acid final concentration to the solution is 5%, then crosses 731 type cation exchange resin columns, uses bismuth potassium iodide to detect at any time ion exchange liquid, collection contains the ion exchange liquid of non-alkaloid components, adds the NaOH adjust pH to neutral again in the ion exchange liquid that contains non-alkaloid components;
Three, the ion exchange liquid that contains non-alkaloid components of gained neutrality in the step 2 obtains the non-alkaloid cream that relative density is 1.15g/ml at 25～50 ℃ of lower concentrating under reduced pressure, and then drying makes the non-alkaloid powder under vacuum;
Four, get the non-alkaloid powder 100g that step 3 makes, then add the starch of 100g and the purified water of 50～100g and make pill, namely finish the preparation of the non-alkaloid ball that the Fructus Toosendan that is used for the treatment of gastric ulcer and Rhizoma Corydalis extract.
In the present embodiment Fructus Toosendan have circulation of qi promoting soothing the liver, let out the effect of liver-fire clearly; Rhizoma Corydalis has the blood-activating and qi-promoting pain relieving.Two medicines match, a gas one blood, a cold temperature, the merit of tool Shugan Qingre, promoting the circulation of QI to relieve pain.
Fructus Toosendan and Rhizoma Corydalis are all available from Heilongjiang University of Chinese Medicine's traditional Chinese medical science hall outpatient service in the present embodiment; Through identifying that Fructus Toosendan is the dry mature fruit of Meliaceae plant Fructus Toosendan (Melia toosendan Sieb.Et Zucc.), Rhizoma Corydalis is the dry tuber of papaveraceae plant corydalis (Corydalis yanhusuo W.T.Wang).
Relative density is the non-alkaloid cream of 1.15g/ml in the present embodiment step 3, is the density with respect to water.
Gained non-alkaloid cream in the step 3 in the present embodiment is by known to the chemico-analytic method detection.
The specific embodiment two: present embodiment with the difference of the specific embodiment one is: in the step 1 Rhizoma Corydalis of 2.5Kg and the Fructus Toosendan of 2.5Kg are mixed.Other step and parameter are identical with the specific embodiment one.
The specific embodiment three: the difference of present embodiment and the specific embodiment one is: the quality ratio of cation exchange resin and solution is 3: 50 in the step 2.Other step and parameter are identical with the specific embodiment one.
The specific embodiment four: the difference of present embodiment and the specific embodiment one is: the flow velocity of crossing 731 type cation exchange resin columns in the step 2 be 1～1.5 resin volume/hour.Other step and parameter are identical with the specific embodiment one.
Embodiment 1:
Being used for the treatment of the Fructus Toosendan of gastric ulcer and the preparation method of the non-alkaloid ball that Rhizoma Corydalis extracts carries out as follows:
One, the Rhizoma Corydalis of 2.5Kg and the Fructus Toosendan of 2.5Kg are mixed, then add the distilled water account for 8 times of Rhizoma Corydalis and Fructus Toosendan gross masses and decoct 2h, collect decoction liquor, add again the distilled water account for 6 times of Rhizoma Corydalis and Fructus Toosendan gross masses and decoct 2h, merge decoction liquor and also be concentrated into the concentrated solution that obtains 5000mL;
Two, adding mass concentration in the concentrated solution is that 95% ethanol to final concentration is 75%, filter after leaving standstill 24h, then steam the ethanol in the filtrate, add water to again 5000mL, adding concentrated hydrochloric acid hydrochloric acid final concentration to the solution is 5%, then crosses 731 type cation exchange resin columns, uses bismuth potassium iodide to detect at any time ion exchange liquid, collection contains the ion exchange liquid of non-alkaloid components, adds the NaOH adjust pH to neutral again in the ion exchange liquid that contains non-alkaloid components;
Three, the ion exchange liquid that contains non-alkaloid components of gained neutrality in the step 2 obtains the non-alkaloid cream that relative density is 1.15g/ml at 25～50 ℃ of lower concentrating under reduced pressure, and then drying makes the non-alkaloid powder under vacuum;
Four, get the non-alkaloid powder 100g that step 3 makes, then add the starch of 100g and the purified water of 50～100g and make pill, namely finish the preparation of the non-alkaloid ball that the Fructus Toosendan that is used for the treatment of gastric ulcer and Rhizoma Corydalis extract;
Wherein the quality ratio of cation exchange resin and solution is 3: 50 in the step 2;
The flow velocity of crossing 731 type cation exchange resin columns in the step 2 be 1 resin volume/hour.
Present embodiment prepares gained and is used for the treatment of the Fructus Toosendan of gastric ulcer and the non-alkaloid ball (hereinafter to be referred as pill) that Rhizoma Corydalis extracts, and average ball heavily is 100mg.
Test present embodiment gained pill is to the effect of Experimental Gastric Ucler:
Zoopery adopts the acetic acid semar technique to copy the rat gastric ulcer model, and compares with model group experiment and treatment gastric ulcer typical case Western medicine omeprazole; Every group of ten rat gastric ulcer models, each experimental index results averaged.Test index comprises ulcer index, ulcer area, ulcer healing percentage rate, serum interleukin 8 (IL-8), tumor necrosis factor-alpha (TNF-α), neurotensin (NT), platelet activating factor (PAF), the thromboxane B2 (TXB of rat
2) and VEGF (VEGF), cerebral tissue acetylcholine esterase (AchE), gastric tissue prostaglandin E
2(PGE
2) and bFGF (bFGF), rat model VEGF mRNA (VEGFmRNA) and bFGF mRNA (bFGFmRNA) index.
Not dosing model group of rat model ulcer experimental result: ulcer index is 0.911 ± 0.166, and ulcer area is 0.146 ± 0.060mm
2Serum il-8 and TNF-alpha content are respectively 23.66 ± 6.404pg/mL and 451.36 ± 25.47pg/mL; Serum N T and cerebral tissue AchE content are respectively 88.10 ± 12.20pg/mL and 5.38 ± 0.24IU/mL; Blood-serum P AF and TXB
2Content is respectively 651.18 ± 49.39pg/mL and 68.52 ± 8.93pg/mL; Gastric tissue PGE
2Content is 31.56 ± 2.36pg/mL; Serum VEGF and gastric tissue bFGF content are respectively 3.84 ± 0.44ng/mL and 110.77 ± 13.94pg/mL, and VEGFmRNA and bFGFmRNA expression intensity are respectively 0.212 ± 0.013 and 0.91 ± 0.101.
Drugs compared, the result that omeprazole is tested rat model ulcer: ulcer index is 0.400 ± 0.082, and ulcer area is 0.027 ± 0.011mm
2The ulcer healing percentage rate is 70.73%, and rat model serum il-8 and TNF-alpha content are respectively 12.91 ± 3.51pg/mL and 425.43 ± 14.39pg/mL.Rat model serum N T and cerebral tissue AchE content are respectively 132.49 ± 7.97pg/mL and 6.39 ± 0.46IU/mL, and rat model blood-serum P AF and TXB content are respectively 553.07 ± 44.72pg/mL and 30.00 ± 7.64pg/mL, rat model gastric tissue PGE
2Content is 48.87 ± 4.51pg/mL, rat model serum VEGF and gastric tissue bFGF content are respectively 5.83 ± 0.67ng/mL and 122.99 ± 8.38pg/mL, and rat model VEGFmRNA and bFGFmRNA expression intensity are respectively 0.432 ± 0.019 and 1.39 ± 0.075.
Present embodiment gained pill is to rat ulcer model test result (in the bracket for omeprazole under the same conditions to the result of rat model ulcer test): ulcer index is 0.450 ± 0.096 (0.400 ± 0.082), and ulcer area is 0.037 ± 0.017mm
2(0.027 ± 0.011mm
2); The ulcer healing percentage rate is 67.07% (70.73%), and rat model serum il-8 and TNF-alpha content are respectively 11.26 ± 1.92pg/mL (12.91 ± 3.51pg/mL) and 410.06 ± 7.25pg/mL (425.43 ± 14.39pg/mL).Rat model serum N T and cerebral tissue AchE content are respectively 168.13 ± 18.90pg/mL (132.49 ± 7.97pg/mL) and 6.76 ± 0.35IU/mL (6.39 ± 0.46IU/mL), rat model blood-serum P AF and TXB content be respectively 538.62 ± 26.56pg/mL (553.07 ± 44.72pg/mL) and 28.77 ± 6.30pg/mL (30.00 ± 7.64pg/mL), rat model gastric tissue PGE
2Content is 55.94 ± 2.93pg/mL (48.87 ± 4.51pg/mL), rat model serum VEGF and gastric tissue bFGF content be respectively 6.21 ± 0.77ng/mL (5.83 ± 0.67ng/mL) with 131.93 ± 12.64pg/mL (122.99 ± 8.38pg/mL), rat model VEGFmRNA and bFGFmRNA expression intensity are respectively 0.455 ± 0.035 (0.432 ± 0.019) and 1.46 ± 0.035 (1.39 ± 0.075).
The effect of present embodiment gained pill Dichlorodiphenyl Acetate smear type rats models of gastric ulcer shows for the ulcer index ulcer area and descends, ulcer obtains healing, reduce rat blood serum IL-8 and TNF-alpha content, rising serum N T and cerebral tissue AchE content, reduce blood-serum P AF and TXB2 content, rising gastric tissue PGE
2Content increases serum VEGF and gastric tissue bFGF content, strengthens the index aspects such as gastric tissue VEGFmRNA and bFGFmRNA expression.
The result compares with treatment ulcer typical medicaments Omeprazole test, and present embodiment gained pill is at rat model serum N T and cerebral tissue AchE content, rat model gastric tissue PGE
2Content, VEGF and bFGF content, VEGFmRNA and bFGFmRNA expression intensity achievement data all will be higher than the Omeprazole test result; And other index also all is close with the Omeprazole test data.Show that thus pill of the present invention has preferably healing effect to ulcer treatment.
Embodiment 2:
Be used for the treatment of the preparation method of Fructus Toosendan and the non-alkaloid ball that Rhizoma Corydalis extracts of gastric ulcer, with the difference of embodiment 1 be: the Rhizoma Corydalis of 1.25Kg and the Fructus Toosendan of 2.5Kg are mixed, and other step and parameter are identical with embodiment 1.
Present embodiment gained gained pill is to rat ulcer model test result (in the bracket for omeprazole under the same conditions to the result of rat model ulcer test): ulcer index is 0.405 ± 0.068 (0.400 ± 0.082), and ulcer area is 0.031 ± 0.015mm
2(0.027 ± 0.011mm
2); The ulcer healing percentage rate is 62.60% (70.73%), and rat model serum il-8 and TNF-alpha content are respectively 10.76 ± 1.84pg/mL (12.91 ± 3.51pg/mL) and 400.10 ± 6.85pg/mL (425.43 ± 14.39pg/mL).Rat model serum N T and cerebral tissue AchE content are respectively 156.32 ± 16.80pg/mL (132.49 ± 7.97pg/mL) and 6.47 ± 0.33IU/mL (6.39 ± 0.46IU/mL), rat model blood-serum P AF and TXB content be respectively 526.82 ± 25.65pg/mL (553.07 ± 44.72pg/mL) and 26.42 ± 5.85pg/mL (30.00 ± 7.64pg/mL), rat model gastric tissue PGE
2Content is 51.43 ± 2.56pg/mL (48.87 ± 4.51pg/mL), rat model serum VEGF and gastric tissue bFGF content be respectively 5.91 ± 0.72ng/mL (5.83 ± 0.67ng/mL) with 122.54 ± 10.25pg/mL (122.99 ± 8.38pg/mL), rat model VEGFmRNA and bFGFmRNA expression intensity are respectively 0.425 ± 0.030 (0.432 ± 0.019) and 1.36 ± 0.038 (1.39 ± 0.075).
Claims (4)
1. the preparation method that is used for the treatment of the non-alkaloid ball that the Fructus Toosendan of gastric ulcer and Rhizoma Corydalis extract is characterized in that it carries out as follows:
One, the Rhizoma Corydalis of 1.25～3.75Kg and the Fructus Toosendan of 2.5Kg are mixed, then add the distilled water account for 8 times of Rhizoma Corydalis and Fructus Toosendan gross masses and decoct 2h, collect decoction liquor, add again the distilled water account for 6 times of Rhizoma Corydalis and Fructus Toosendan gross masses and decoct 2h, merge decoction liquor and also be concentrated into the concentrated solution that obtains 5000mL;
Two, adding mass concentration in the concentrated solution is that 95% ethanol to final concentration is 75%, filter after leaving standstill 24h, then steam the ethanol in the filtrate, add water to again 5000mL, adding concentrated hydrochloric acid hydrochloric acid final concentration to the solution is 5%, then crosses 731 type cation exchange resin columns, uses bismuth potassium iodide to detect at any time ion exchange liquid, collection contains the ion exchange liquid of non-alkaloid components, adds the NaOH adjust pH to neutral again in the ion exchange liquid that contains non-alkaloid components;
Three, the ion exchange liquid that contains non-alkaloid components of gained neutrality in the step 2 obtains the non-alkaloid cream that relative density is 1.15g/ml at 25～50 ℃ of lower concentrating under reduced pressure, and then drying makes the non-alkaloid powder under vacuum;
Four, get the non-alkaloid powder 100g that step 3 makes, then add the starch of 100g and the purified water of 50～100g and make pill, namely finish the preparation of the non-alkaloid ball that the Fructus Toosendan that is used for the treatment of gastric ulcer and Rhizoma Corydalis extract.
2. the preparation method that is used for the treatment of Fructus Toosendan and the non-alkaloid ball that Rhizoma Corydalis extracts of gastric ulcer according to claim 1 is characterized in that in the step 1 Rhizoma Corydalis of 2.5Kg and the Fructus Toosendan of 2.5Kg being mixed.
3. the preparation method of the non-alkaloid ball that extracts of the Fructus Toosendan that is used for the treatment of gastric ulcer according to claim 1 and Rhizoma Corydalis is characterized in that the quality ratio of cation exchange resin and solution is 3: 50 in the step 2.
4. the preparation method of the non-alkaloid ball that extracts of the Fructus Toosendan that is used for the treatment of gastric ulcer according to claim 1 and Rhizoma Corydalis, the flow velocity that it is characterized in that crossing in the step 2 731 type cation exchange resin columns be 1～1.5 resin volume/hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104647581A CN102920788A (en) | 2012-11-16 | 2012-11-16 | Preparation method of non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis for treating gastric ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104647581A CN102920788A (en) | 2012-11-16 | 2012-11-16 | Preparation method of non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis for treating gastric ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102920788A true CN102920788A (en) | 2013-02-13 |
Family
ID=47635813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104647581A Pending CN102920788A (en) | 2012-11-16 | 2012-11-16 | Preparation method of non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis for treating gastric ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102920788A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435135A (en) * | 2014-12-04 | 2015-03-25 | 黑龙江中医药大学 | Method of extracting non-alkaloid from fructus meliae toosendan and rhizoma corydalis |
| CN110327432A (en) * | 2019-08-14 | 2019-10-15 | 胡世甫 | A kind of drug and preparation method thereof for treating gastric ulcer and erosive gastritis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634205A (en) * | 2003-12-30 | 2005-07-06 | 天津大学 | Cataplasm formulation of pain easing Chinese medicine chinaberry fruit and its preparing process |
| WO2011123996A1 (en) * | 2010-04-09 | 2011-10-13 | 铜陵市维新投资咨询有限公司 | Traditional chinese medicinal composition for curing duodenal ulcer and preparation method thereof |
| CN102283902A (en) * | 2010-06-17 | 2011-12-21 | 苏州知微堂生物科技有限公司 | Integrated novel form preparation technology for Sichuan chinaberry powder and production method thereof |
| CN102706999A (en) * | 2012-02-20 | 2012-10-03 | 浙江康恩贝制药股份有限公司 | Analyzing and detecting method for rhizoma corydalis water-soluble non-alkaloid compound |
-
2012
- 2012-11-16 CN CN2012104647581A patent/CN102920788A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634205A (en) * | 2003-12-30 | 2005-07-06 | 天津大学 | Cataplasm formulation of pain easing Chinese medicine chinaberry fruit and its preparing process |
| WO2011123996A1 (en) * | 2010-04-09 | 2011-10-13 | 铜陵市维新投资咨询有限公司 | Traditional chinese medicinal composition for curing duodenal ulcer and preparation method thereof |
| CN102283902A (en) * | 2010-06-17 | 2011-12-21 | 苏州知微堂生物科技有限公司 | Integrated novel form preparation technology for Sichuan chinaberry powder and production method thereof |
| CN102706999A (en) * | 2012-02-20 | 2012-10-03 | 浙江康恩贝制药股份有限公司 | Analyzing and detecting method for rhizoma corydalis water-soluble non-alkaloid compound |
Non-Patent Citations (2)
| Title |
|---|
| 刘高峰等: "北洋金花非生物碱成分的HPLC指纹图谱研究", 《中医药学报》 * |
| 张媛媛: "山豆根非生物碱部位的活性研究", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435135A (en) * | 2014-12-04 | 2015-03-25 | 黑龙江中医药大学 | Method of extracting non-alkaloid from fructus meliae toosendan and rhizoma corydalis |
| CN110327432A (en) * | 2019-08-14 | 2019-10-15 | 胡世甫 | A kind of drug and preparation method thereof for treating gastric ulcer and erosive gastritis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600219B (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
| CN101919979B (en) | Detection method of traditional Chinese medicine composition for soothing liver-qi stagnation and tonifying spleen and removing dampness | |
| CN103800438A (en) | Ligusticum wallichii tea modulator and preparation method thereof | |
| CN109172635B (en) | Preparation method of traditional Chinese medicine composition containing cassia twig | |
| CN102416071B (en) | Medicinal composition with effect of treating insomnia, preparation method and application of medicinal composition | |
| CN106237067B (en) | Diabetes and blood sugar reducing capsule and preparation method thereof | |
| CN103505486A (en) | Lucid ganoderma-American ginseng granule and preparation method thereof | |
| CN105031005A (en) | Micro pills capable of tonifying qi and benefiting blood | |
| CN102920788A (en) | Preparation method of non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis for treating gastric ulcer | |
| CN101822762A (en) | Chinese herbal compound effective composite for treating dysmenorrhea and preparation method and application thereof | |
| CN101897770B (en) | Bone spur capsule and preparation process thereof | |
| CN103830374B (en) | The application in hyperuricemia clearly of three leaf glycolipids | |
| CN107961321B (en) | Extraction process of liuhe pill raw material medicine | |
| CN104435658B (en) | A kind of medicine for ischemia apoplexy prevention and treatment and preparation method thereof | |
| CN108226325A (en) | Roripa montana gives birth to the method for building up of arteries and veins oral liquid composition finger-print | |
| CN1116868C (en) | Concentrated granule medicine of famous decoction formulation and its preparation | |
| CN102631386B (en) | Bupleurum antipyretic and analgesic preparation and technology for preparing same | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| CN111375035B (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN109078115B (en) | Traditional Chinese medicine preparation for treating gastrointestinal hemorrhage and preparation method thereof | |
| CN108066494B (en) | Liquid medicine with frequent nocturia and preparation method thereof | |
| CN106266343A (en) | A kind of preparation method of dispersing brain blood | |
| CN112402515A (en) | Chinese medicinal extract containing insect medicine and preparation method of preparation thereof | |
| CN101371877B (en) | Qi tian dropping pill extract and Qi tian dropping pill as well as method for producing the same | |
| CN105168328A (en) | Kudzuvine root extract, extracting method and dropping pill of kudzuvine root extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130213 |